J&J Seeks Command Position In FcRn Space With Momenta Buyout
Executive Summary
J&J will pay about $6.5bn to acquire Momenta and its potential “pipeline in a pathway” with nipocalimab. Analysts expect this deal may lead to further M&A activity in the anti-FcRn space.
You may also be interested in...
In Vivo’s Deals Of The Year 2020: Winners Revealed
For In Vivo's 13th annual Deals of the Year contest, we selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.
In Vivo’s Deals Of The Year 2020: Cast Your Vote!
It is time for In Vivo's 13th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
Argenx Advances Efgartigimod Into China With Zai Lab Pact
Having just filed efgartigimod in the US, the European biotech has signed up Zai Lab to help develop and sell the potential autoimmune blockbuster in China, where an estimated 200,000 people live with myasthenia gravis.
Need a specific report? 1000+ reports available
Buy Reports